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Abstract: The surfaces of the abdomen and pelvis are an important anatomic site for the dissemination of gastrointestinal and gyneco-
logic malignancy. This transcoelomic spread of cancer cells gives rise to peritoneal carcinomatosis which, without special treatments, is a 
fatal manifestation of these diseases. In order to control peritoneal carcinomatosis cytoreductive surgery to remove gross disease is com-
bined with perioperative intraperitoneal and perioperative intravenous chemotherapy to eradicate microscopic residual disease. Chemo-
therapy agents are selected to be administered by the intraperitoneal or intravenous route based on their pharmacologic properties. A peri-
toneal-plasma barrier which retards the clearance of high molecular weight chemotherapy from the peritoneal cavity results in a large ex-
posure of small cancer nodules on abdominal and pelvic surfaces. Tissue penetration is facilitated by moderate hyperthermia (41-42ºC) of 
the intraperitoneal chemotherapy solution. A constant dose of chemotherapy agent and volume of carrier solution based on body surface 
area allows prediction of systemic drug exposure and systemic toxicity. Timing of the chemotherapy as a planned part of the surgical 
procedure to maximize exposure of all peritoneal surfaces is crucial to success. 
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INTRODUCTION 
The peritoneal surface remains an important failure site for pa-
tients with gastrointestinal and gynecological malignancies. Besides 
the lymphatic and hematogenous routes of dissemination, transco-
elomic spread of tumor cells is an acknowledged phenomenon ulti-
mately giving rise to peritoneal carcinomatosis (PC). This intraperito-
neal spread may occur before surgery as a direct consequence of full-
thickness invasion of the involved organ by tumor and subsequently 
exfoliation of tumor cells in the peritoneal cavity. Also, intraperito-
neal spread may be the result of surgical trauma that causes release of 
tumor cells from transected lymph and blood vessels and manipula-
tion of the primary tumor. For example in a review of 2756 patients 
by Jayne et al., they reported the incidence of PC at the time of initial 
surgery to be 7.7% [1]. A review of colonic cancer patients who have 
recurrences suggests that peritoneal seeding occurred in 25-35% of 
patients [2]. 
NATURAL HISTORY OF PERITONEAL CARCINOMATO-
SIS  
Nevertheless, little was done to clarify the impact of peritoneal 
seeding upon survival until the report of Chu and colleagues was 
published [3]. These investigators studied 100 patients with non-
gynecologic malignancy that had biopsy-proven peritoneal carcino-
matosis. The mean survival of 45 colorectal cancer patients was 8.5 
months, of 20 pancreas cancer patients 2.4 months, and 6 gastric can-
cer patients 2.2 months. The presence or absence of ascites was an 
important poor prognostic variable in all of these patients.  
In 2000 Sadeghi and coworkers reported on 370 patients with 
peritoneal carcinomatosis from non-gynecologic malignancies who 
were enrolled in a European prospective multicenter trial (Evolution 
of Peritoneal Carcinomatosis 1 [EVOCAPE 1]) [4]. These patients 
had the benefit of fluorouracil (5-FU)-based systemic chemotherapy, 
but the results were remarkably similar to those reported by Chu a 
decade earlier. The mean survival of 118 patients with carcinomatosis 
from colorectal cancer was 6.0 months, of 58 patients with pancreatic 
cancer 2.9 months, and of 125 patients with gastric cancer 6.5 
months. 
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In 2002 Jayne and colleagues from Singapore used a database of 
3019 colorectal cancer patients to identify 349 (13%) with peritoneal 
carcinomatosis [1]. Of special interest were the 125 patients (58%) 
who had synchronous primary colorectal cancer and peritoneal im-
plants. The median survival of those patients was only 7 months. The 
authors reported that survival was adversely affected by the extent of 
the peritoneal carcinomatosis and the stage of the primary cancer. 
REVISED HYPOTHESIS REGARDING CARCINOMATOSIS 
More recent chemotherapy based on the use of oxaliplatin, iri-
notecan and biological agents has improved survival in patients with 
metastatic colon cancer to 16-20 months [5-7]. Unfortunately, these 
recent trials do not provide data of results in patients with isolated PC 
and only address results in a collection of patients with metastatic 
colonic cancer at many different anatomic sites. In the past oncolo-
gists have assumed that PC is equal to distant metastases and as such 
regarded it as an incurable component of intraabdominal malignancy. 
PC has been regarded as beyond current treatment modalities. Over 
the last two decades a group of oncologists have worked using a re-
vised hypothesis. Novel therapeutic approaches have emerged for 
patients with isolated peritoneal metastases of gastrointestinal cancer, 
ovarian cancer and primary peritoneal malignancies. These investiga-
tors all consider PC as a local-regional disease warranting local-
regional chemotherapy (intraperitoneal) to treatment. Spratt et al., 
reported for the first time in 1980 the use of heated triethylenethio-
phosphor-amide (thiotepa) in a patient with pseudomyxoma peritonei 
[8]. Koga et al. reported the use of intraperitoneal chemotherapy in 23 
gastric cancer patients with PC [9]. Speyer in 1980 used normother-
mic intraperitoneal 5-FU and methotrexate in 16 patients with PC 
[10]. 
ROLE FOR CYTOREDUCTIVE SURGERY 
A second essential part of the modern management of PC is cy-
toreductive surgery with peritonectomy procedures. The underlying 
rationale of a combined approach was that on one hand an aggressive 
surgical approach combining visceral resections and peritonectomy 
procedures should address the macroscopic disease whereas pe-
rioperative intraperitoneal chemotherapy was aimed at residual mi-
croscopic disease [11]. The perioperative intraperitoneal chemother-
apy includes Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 
and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC). 
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toneal and intravenous chemotherapy) Intraoperative Chemohyper-
thermia. This two-component approach of PC treatment requires that 
chemotherapy be used as a planned part of the surgical procedure. 
Critical to the success is proper timing of the chemotherapy in its 
relation to the surgery. This innovation of combined treatment of 
cytoreductive surgery plus perioperative intraperitoneal chemother-
apy may be the paradigm shift responsible for recent successes versus 
prior failures in treating PC patients. 
RESULTS TO DATE IN TREATING CARCINOMATOSIS 
Several phase II studies have explored the intraperitoneal route of 
drug delivery and show promising results in a variety of PC patients. 
In colorectal cancer with PC overall survival rates between 25% and 
47% are reported [12-17]. These reports from many different institu-
tions stand in strong contrast with historical control groups and pa-
tients treated with systemic chemotherapy where the mean and me-
dian overall survival was 6.0 months and 3.1 months [4]. Verwaal et 
al. in a phase III trial randomized patients with colorectal PC to pal-
liative surgery followed by fluorouracil-leucovorin systemic chemo-
therapy versus maximal cytoreduction plus HIPEC with Mitomycin C 
and subsequent systemic chemotherapy [18]. This report showed a 
significant survival benefit for the HIPEC arm with a median survival 
of 22.3 months versus 12.6 months in the control group. Glehen et al. 
collected data retrospectively on 506 PC patients from 28 institutions 
treated with cytoreductive surgery and perioperative intraperitoneal 
chemotherapy [19]. He reported an overall median survival of 19.2 
months. Patients in whom cytoreduction was complete had a median 
survival of 32.4 months versus 8.4 months in the patients with in-
complete cytoreduction. 
There is no doubt that the clinical evidence in the medical litera-
ture supporting the combined approach of cytoreductive surgery and 
perioperative intraperitoneal chemotherapy is growing [20-24]. What 
is lacking is clear understanding of the pharmacology of perioperative 
use of chemotherapy in the treatment of peritoneal surface malig-
nancy. It is possible that increased safety and important treatment 
innovations may originate from analyzing the pharmacologic data. 
This review aims to clarify the pharmacokinetic and pharmacody-
namic data currently available regarding the intraperitoneal delivery 
of cancer chemotherapy agents in patients with PC. 
THE PERITONEAL PLASMA BARRIER 
The rationale of administering chemotherapeutic drugs into the 
peritoneal cavity is based on the relative transport barrier which is 
formed by the tissue surrounding the peritoneal space. The perito-
neum is a complex three-dimensional organ covering the abdomino-
pelvic organs and the abdominal wall. It contains a large potential 
space. The most elaborate description of the ultra structure of the 
peritoneum in man goes back to 1941 by Baron et al. [25]. The peri-
toneum consists of a monolayer of mesothelial cells supported by a 
basement membrane and five layers of connective tissue which ac-
count for a total thickness of 90 m. The connective tissue layers 
include interstitial cells and a matrix of collagen, hyaluron, and pro-
teoglycans. The cellular component consists of pericytes, parenchy-
mal cells and blood capillaries. The complex is often referred to as 
the peritoneal membrane. This description is a working model de-
rived from research regarding the peritoneum as a dialysis membrane. 
The accepted function of the peritoneum is twofold. First, it re-
duces friction between intraabdominal organs and the abdominal wall 
by producing a lubricant solution made of glycosaminoglycans and 
phospholipids [26]. Secondly, it is of major importance together with 
lymphoid aggregates dispersed on the visceral and parietal perito-
neum in the host defense against intraabdominal infections. A third 
suggested function of the peritoneum in malignancy may be its role as 
a first line of defense against peritoneal carcinomatosis [27]. Any 
disruption in the peritoneal lining facilitates the adhesion-invasion 
cascade of tumor cells, resulting in the development of peritoneal 
tumor nodules on the abdominal or pelvic surface [27, 28]. 
Contrary to intuitive thinking the elimination of the mesothelial 
lining as performed during peritonectomy procedures does not sig-
nificantly alter the pharmacokinetic properties of the peritoneum in 
the transport of chemotherapeutic agents from the peritoneal cavity to 
the plasma compartment. Flessner et al. demonstrated in a rodent 
model that neither removal of the stagnant fluid layer on the mesothe-
lium nor removal of the mesothelial lining influenced the mass trans-
fer coefficient (MTC) over the barrier [29]. Indirect evidence support-
ing this hypothesis in humans can be derived from the fact that the 
extent of the peritonectomy in PC patients does little to alter the in-
traperitoneal chemotherapy pharmacokinetics of Mitomycin C or 5-
fluorouracil [30, 31]. Basic research rather demonstrates that not only 
the mesothelial lining but also the blood capillary wall and the sur-
rounding interstitial matrix are the principal barrier for clearance of 
molecules from the abdominopelvic space [32]. 
Most basic research concerning the pharmacokinetic properties of 
the peritoneum is derived from the peritoneal dialysis literature [33]. 
A simplified mathematical diffusion model considers the plasma to 
be a single compartment separated by an effective membrane from 
another single compartment, the peritoneal cavity (Fig. 1). This re-
sults in the following equation: 
Rate of mass transfer = PA (CP - CB) where PA = permeability 
area, CP = concentration in peritoneal cavity and CB = concentration 
in the blood. 
Although this offers a simple conceptual model of transport and 
states the importance of the effective exposure area, it only offers 
quantitative predictability once PA is empirically determined for each 
drug. It also does not offer insight into the actual tissue penetration at 
the level of the peritoneal membrane. Neither does it predict penetra-
tion of chemotherapy into the tumor nodules which is the single most 
important factor determining response to cancer treatment.  
 
 
 
 
 
 
 
 
 
Fig. (1). Traditional two-compartment model of peritoneal transport in 
which transfer of a drug from the peritoneal cavity to the blood occurs 
across the “peritoneal membrane”. The permeability-area product 
(PA) governs this transfer and can be calculated by measuring the rate 
of drug disappearance from the cavity and dividing by the overall 
concentration difference between the peritoneal cavity and the blood 
(or plasma). CB = the free drug concentration in the blood (or plasma); 
VB = volume of distribution of the drug in the body; Cp = the free drug 
concentration in the peritoneal fluid; Vp  = volume of the peritoneal 
cavity. (Dedrick R.L., Flessner M.F.: Pharmacokinetic problems in perito-
neal drug administration: Tissue penetration and surface exposure. J Natl 
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PHARMACOKINETIC RATIONALE OF PERIOPERATIVE 
INTRAPERITONEAL CANCER CHEMOTHERAPY 
Intraperitoneal administration of chemotherapeutic agents gives 
high response rates in PC patients because the peritoneal plasma bar-
rier provides dose-intensive therapy. Based on peritoneal dialysis 
research, Dedrick et al. in 1978 concluded that the peritoneal perme-
ability of a number of hydrophilic anticancer drugs may be consid-
erably less than the plasma clearance of that same drug. This results 
in a significantly higher concentration in the peritoneal cavity as 
compared to the plasma after intraperitoneal administration [34]. This 
concentration difference offers the opportunity of exposing the resid-
ual tumor cells after cytoreduction to high doses of chemotherapeutic 
agents with reduced systemic concentrations and lower systemic 
toxicity. This advantage is expressed by the Area Under the Curve 
(AUC) ratios of intraperitoneal versus plasma exposure. Table 1 pre-
sents molecular weight and AUC IP/IV for drugs in clinical or ex-
perimental use in PC patients [35]. 
An important consideration is that high intraperitoneal concentra-
tion or AUC IP/IV does not automatically confer a greater efficacy. 
Even with greatly elevated intraperitoneal cancer chemotherapy con-
centrations, there may be limited penetration of the chemotherapeutic 
agent into the peritoneal tumor target. The ideal drug for intraperito-
neal chemotherapy has a high peritoneal tissue concentration as a 
result of direct intraperitoneal administration and a high penetration 
into the cancer nodule. This should occur along with slow diffusion 
through the capillary endothelium deep in the subperitoneal space of 
the cancer chemotherapy solution. Low systemic concentrations and 
reduced systemic toxicity are maintained by rapid metabolism and 
excretion of drug within the body compartment.  
The marked increase in exposure of peritoneal surfaces to chemo-
therapy solution as compared to plasma is illustrated in Fig. (2). The 
chemotherapy agent, paclitaxel, has a high molecular weight (853.9 
Daltons) and is slow to cross the peritoneal cavity to plasma barrier. 
The naked molecule of paclitaxel is highly lipophilic. It is unique in 
cancer chemotherapy in that the intravascular or intraperitoneal ad-
ministration of the drug requires it to be suspended in a detergent that 
maintains the drug in solution. The detergent molecules surround the 
paclitaxel molecule giving it additional size and a hydrophilic charac-
ter. This large molecular size and hydrophilic behavior of the com-
plex molecule result in slow passage across the peritoneal to plasma 
barrier. The AUC ratio for paclitaxel is 1000 (Table 1). 
PHARMACOKINETIC RATIONALE OF PERIOPERATIVE 
INTRAVENOUS CANCER CHEMOTHERAPY 
New pharmacologic data suggests altered parmacodynamics of 
intravenously administered cancer chemotherapy drugs when used 
intraoperatively during a HIPEC procedure. Fig.  (3)  shows 5-
fluorouracil concentrations in the plasma, peritoneal fluid and tumor 
nodules after intravenous administration at the beginning of the 
HIPEC procedure. The intravenous fluorouracil is rapidly transported 
from the plasma compartment to the expanded peritoneal cavity. 
There it is retained in the artificial ascites created by the HIPEC for a 
substantial amount of time before a reduced rate of reabsorption into 
the systemic compartment occurs. Our initial data suggest that the 
artificial ascites created by the HIPEC may provide a reservoir for the 
intravenous administered drug. The intraoperative administration of 
intravenous cancer chemotherapy drugs may offer a pharmacologic 
advantage in killing residual tumor cells after cytoreduction. Timing 
of intravenous cancer chemotherapy (intraoperative versus pre- or 
postoperative) emerges as a new variable which may affect efficacy 
of cancer chemotherapy drugs in treating patients with a peritoneal 
surface malignancy. 
TISSUE DISTRIBUTION AND PENETRATION DEPTH 
The simplified two-compartment model described above may not 
provide an adequate theoretical model for penetration of the intraop-
eratively administered (either intravenous or intraperitoneal) chemo-
therapy into the peritoneal wall and into the tumor nodules. Dedrick 
et al. proposed a mathematical model seen in Fig. (4) addressing the 
tissue penetration of low-molecular weight molecules [36, 37]. The 
drug diffuses from its peritoneal concentration, Cp, to its blood con-
centration, CB, along an exponential concentration gradient over the 
peritoneum and preperitoneal tissues. The extracellular ‘deep’ con-
centration, Ce, can then be calculated according to the formula: 
Ce = CB + (Cp - CB) exp[ - (k/D)
1/2x] 
In this formula k (min
-1) is the rate constant for removal of the ac-
tive drug from the tissue. Movement through the tissue is character-
ized by the diffusivity, D (cm
2/min) and x is the distance from the 
serosal surface (cm). This model implies that there is an exponential 
Table 1. Molecular Weight and Area Under the Curve Ratios of In-
traperitoneal Exposure to Systemic Exposure of Chemothera-
peutic Agents Used to Treat Peritoneal Carcinomatosis 
Drug  Molecular Weight (Daltons) 
Area Under the 
Curve Ratio 
5-Fluorouracil 130.08  250 
Carboplatin 371.25  10 
Cisplatin 300.1 7.8 
Docetaxel 861.9  552 
Doxorubicin 579.99  230 
Etoposide 588.58  65 
Floxuridine 246.2  75 
Gemcitabine 299.5  500 
Irinotecan 677.19 N/A 
Melphalan 305.2  93 
Mitomycin C  334.3  23.5 
Mitoxantrone 517.41 115-255 
Oxaliplatin 397.3  16 
Paclitaxel  853.9 1000 
Pemetrexed 597.49  40.8 
 
 
 
 
 
 
 
 
Fig. (2). Pharmacokinetic study of concentration versus time for intraperito-
neal paclitaxel. The chemotherapy agent at 30 mg/m
2 was instilled directly 
into the peritoneal cavity as rapidly as possible in a 1.5% dextrose perito-
neal dialysis solution. The concentration of paclitaxel was determined in 
peritoneal fluid and in plasma for 24 hours. Using Pharmacologic Data to Plan Clinical Treatments  Current Drug Discovery Technologies, 2009, Vol. 6, No. 1    75 
concentration decrease of the drug from abdominopelvic cavity 
across the membrane to the plasma compartment. Consequently, the 
depth of penetration of an effective chemotherapy concentration is 
very limited and is in the order of 1 to 2 mm [38, 39]. Ozols et al. 
confirmed adriamycin penetrating only 4-6 cell layers of tumor on the 
diaphragm in a rodent model [40]. In all likelihood there is a variable 
penetration for each drug and type of tumor. 
This has important consequences for implementing perioperative 
chemotherapy in PC patients. The cytoreduction needs to eliminate 
all tumor deposits greater than 1-2 mm for the subsequent intraperito-
neal chemotherapy to be effective. Clinical data to support this phar-
macologic prediction is strong; in univariate and multivariate analysis 
the complete cytoreduction (cancer nodules  2.5 mm) is the single 
most important prognostic factor [15-19].  
In order to describe the pharmacology of both intravenous and in-
traperitoneal chemotherapy used after cytoreduction to treat PC a 
revised theoretical model is needed. Fig.  (5) shows a three-
compartment model constructed of a body compartment, intermediate 
compartment (peritoneal and preperitoneal tissues with tumor nod-
ules) and peritoneal fluid. The movement of chemotherapy molecules 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Pharmacodynamics during hyperthermic intraperitoneal chemotherapy (HIPEC) after intravenous administration of 400 mg/m
2 of 5-
fluorouracil given simultaneously with intraperitoneal chemotherapy in 3 liters of chemotherapy solution. (Van der Speetan K., Stuart O.A., Mahtsme 
H., Sugarbaker P.H.: Pharmacology of perioperative 5-fluorouracil, in press, 2009). 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Conceptual diagram of tissue adjacent to the peritoneal cavity. Cp = the free drug concentration in the peritoneal fluid; CB = the free drug 
concentration in the blood (or plasma). Solid line shows the exponential decrease in the free tissue interstitial concentration, Ce, as the drug diffuses 
down the concentration gradient and is removed by loss to the blood perfusing the tissue. Also shown are the characteristic diffusion length, x0, at 
which the concentration difference between the tissue and the blood has decreased to 37% of its maximum value, and 3x0, at which the difference has 
decreased to 5% of its maximum value. (Dedrick R.L., Flessner M.F.: Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and 
surface exposure. J Natl Cancer Inst 1997; 89(7): 480-87). 76    Current Drug Discovery Technologies, 2009, Vol. 6, No. 1  Speeten et al. 
from blood to peritoneal fluid through the intermediate compartment 
should be rapid because of the extensive arterial and portal venous 
blood delivery to the intermediate tissues. The movement of chemo-
therapy molecules from peritoneal fluid to portal blood would be less 
rapid. 
The number of variations in intraperitoneal chemotherapy treat-
ment protocols is extensive. All these variations reflect attempts to 
improve diffusivity D, decrease the rate constant k, permeability P or 
effective membrane area A. A non-exhaustive list of factors influenc-
ing these values and thus response of the peritoneal metastases to the 
drug is listed in Table 2. Some of these will be explored in greater 
detail. 
TEMPERATURE 
Adding hyperthermia to intraperitoneal chemotherapy may in-
crease the tumor response to cancer chemotherapy drugs by several 
mechanisms. First, heat alone has a direct anti-tumor effect. Hyper-
thermia above 41°C induces selective cytotoxicity of malignant cells. 
Several mechanisms have been proposed: impaired DNA repair, pro-
tein denaturation and inhibition of oxidative metabolism in the micro-
environment of malignant cells leading to increased acidity, lysoso-
mal activation and increased cell death [41, 42]. Cells are known to 
react to protein denaturation by up regulation of heat shock proteins. 
This induces the development of thermal tolerance in tumor cells 
[43]. Thermal tolerance may cause the clinical importance of this first 
mechanism to be limited. Second, the cytotoxic effects of some che-
motherapeutic agents are augmented by applying mild hyperthermia. 
Such augmented effects were postulated for doxorubicin [44], plati-
num complexes [45, 46], mitomycin C [46], melphalan [47], do-
cetaxel, irinotecan and gemcitabine [48]. Third, this increased re-
sponse may be the consequence of the altered penetration depth of the 
chemotherapeutic agent [49, 50]. 
Table 2. Variables Influencing the Response of Peritoneal Carcinoma-
tosis to Perioperative Chemotherapy 
Temperature 
Dose of intraperitoneal chemotherapy 
Distribution of chemotherapy solution and heat 
Timing of chemotherapy in relation to the timing of the surgical intervention 
Type of carrier solution 
Pressure 
Volume of carrier solution 
Duration of instillation 
Vasoactive agents 
Macromolecular vehicles 
Drug sensitivity of the tumor 
Size of residual tumor nodules 
 
Jacquet and colleagues studied the changes in the penetration of 
intraperitoneal chemotherapy that are induced by moderate hyper-
thermia. Large and statistically significant increases in the amount of 
doxorubicin within tissues were demonstrated. The tissues in direct 
contact with the intraperitoneal chemotherapy were most affected. 
The concentration of doxorubicin in small bowel was doubled using 
intraperitoneal doxorubicin plus heat; a similar finding occurred for 
omental tissue and bladder tissue. Tissues at a distance such as heart 
muscle, did not show an increased concentration with heat. The heat 
utilized by Jacquet and colleagues within the peritoneal cavity was 
41.5 to 42 ºC in this rat model [50]. 
PRESSURE 
Dedrick et al. postulated that the penetration distance is equal to 
the square root of the ratio of the tissue diffusivity and the rate con-
stant for drug removal from the tissue (D/k)
1/2. Unpublished observa-
tions by Flessner in a rat model showed a doubling of the extracellu-
lar space in the anterior abdominal wall of rats when the pressure of 
intra-abdominal peritoneal dialysis solution was raised from 0 to 4 cm 
H2O [29]. An increased effective diffusivity was postulated. 
Animal experiments [51, 52] confirmed the increased intratu-
moral accumulation and antitumor effect of intraperitoneal doxorubi-
cin and cisplatin when the intraabdominal pressure was raised. In-
creased intraabdominal pressure is thought to generate a convective 
flux that forces the drug from the peritoneal cavity into the subperito-
neal tissue. At the same time intraabdominal pressure may counteract 
the hydraulic capillary pressure and slow the outflow of the drug to 
the body compartment. Measurement of local cisplatin concentrations 
along the radii of peritoneal tumor nodules showed platinum penetra-
tion far beyond the 1 mm limit advocated by Los et al. [39]. The 
clinical limit of usable intraabdominal pressure enhancement is dic-
tated by respiratory and hemodynamic tolerance. Clinical applications 
of HIPEC in intraabdominal pressure settings so far has been limited 
to palliating debilitating malignant ascites with laparoscopic HIPEC 
at 10-15 mm Hg [53, 54]. 
CARRIER SOLUTION 
A variety of carrier solutions have been applied in different 
treatment protocols. Hypotonic, isotonic and hypertonic solutions 
were explored with both low and high molecular weight chemother-
apy molecules. The ideal carrier solution should enhance the expo-
sure of the peritoneal surface and residual tumor cells to the che-
motherapeutic agent. This is especially important in the setting of 
EPIC where maintenance of a high dwell volume of perfusate over a 
prolonged time period improves the distribution of the drug and the 
effectiveness of the treatment. Chemotherapy solutions of isotonic 
and hypertonic salt, dextrose, hetastarch or icodextrin solutions have 
been explored. In an EPIC setting a high molecular weight solution 
 
 
 
 
 
 
 
 
 
Fig. (5). Three-compartment model of peritoneal transport in which 
transfer of a drug from the peritoneal cavity to the blood occurs across 
the peritoneal membrane and preperitoneal tissues. In these tissues the 
peritoneal surface cancer nodules are located. The permeability-area 
product (PA) governs this transfer and can be calculated by measuring 
the rate of drug disappearance from the cavity and dividing by the 
overall concentration difference between the peritoneal cavity and the 
blood (B). CB = the free drug concentration in the blood (or plasma); VB 
= volume of distribution of the drug in the body; CP = the free drug 
concentration in the peritoneal fluid; VP  = volume of the peritoneal 
cavity.  (Modified from Dedrick R.L., Flessner M.F.: Pharmacokinetic 
problems in peritoneal drug administration: Tissue penetration and surface 
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that maintains an artificial ascites showed a higher drug availability 
because the total drug exposure depends not only on the active drug 
but also on the carrier solution that maintains the peritoneal fluid 
volume [55-57].  
In a HIPEC setting with a relatively short dwell time, one could 
theoretically expect a pharmacodynamic advantage of a hypotonic 
carrier through the mechanism of increased tissue and tumor absorp-
tion. Contrary to experimental studies supporting this hypothesis, 
Elias et al. [58] showed in humans no increase in tumor penetration. 
A concomitant high incidence (50%) of postoperative peritoneal 
bleeding and severe thrombocytopenia has contraindicated the further 
clinical use of hypotonic carriers. 
VOLUME OF CHEMOTHERAPY SOLUTION 
Since peritoneal metastases and free floating tumor cells can be 
present anywhere on the peritoneal surface, the entire surface of the 
abdominal and pelvic cavity is the target. Substantial differences in 
body composition of patients and differences in the actual HIPEC 
technique (open versus closed abdomen) will result in a wide variety 
of perfusate volumes. In current practice the volume of the perfusate 
is chosen quite arbitrary. Following the above stated (equation) con-
cerning mass transfer over the peritoneal-plasma membrane increas-
ing the solution contact area A improves the mass transfer. Keshaviah 
demonstrated a linear rise in mass transfer in 10 patients who were 
dialyzed with different volumes ranging from 0.5 up to 3 liters [59]. 
Elias first published the importance of volume of chemotherapy in 
determining systemic exposure to the drug [60]. Sugarbaker et al. 
carried out a clinical investigation where 2 versus 4 versus 6 liters of 
chemotherapy solution were administered. The dose of chemotherapy 
solution in these studies was constant. They showed that a more di-
lute intraperitoneal chemotherapy concentration retarded the clear-
ance of chemotherapy and lead to a lesser systemic toxicity [61]. 
Also, it must be assumed that the less concentrated chemotherapy 
would, by the diffusion model, penetrate less into the cancer nodules 
and into normal tissues. These authors determined it necessary to 
regulate not only the chemotherapy dose but also the volume of che-
motherapy solution by the patient’s body surface area. 
A consistent drug dose and chemotherapy solution volume may 
be the optimal method to predict a maximal treatment in the abdomen 
with a predictable bone marrow toxicity. Sugarbaker and colleagues 
suggested that variable volume is a dangerous practice with unpre-
dictable systemic toxicities [61]. If chemotherapy solution is adminis-
tered until the abdomen is full the contact area will increase. If the 
contact area is variable the total absorption of drug cannot be pre-
dicted.  
VASOACTIVE AGENTS 
The literature concerning the effects of vasoactive substances in 
regulating peritoneal blood flow and tumor blood flow is extensive. 
These agents may contribute to a delayed clearance from the perito-
neal cavity because the blood flow in the peritoneal and subperitoneal 
vascular network will control, in large part, the movement of mole-
cules across the peritoneal and subperitoneal tissues. General state-
ments regarding the effects of vasoactive agents are confusing and 
sometimes contradictory due to the variety of experimental systems, 
complex interactions of local-regional and systemic effects of vaso-
pressive agents, and large differences between the neovasculature of 
tumor nodules and normal capillaries. Both intravenous and intraperi-
toneal administration of vasoactive molecules in combination with 
chemotherapeutic drugs has been explored [36, 62, 63]. A preclinical 
study of the use of an intraperitoneal epinephrine plus intraperitoneal 
cisplatin in a rat model with PC showed a direct correlation between 
the intraperitoneal epinephrine concentration and cisplatin accumula-
tion in rat peritoneal tumor nodules [64]. Recently, Molucon-Chabrot 
and colleagues for the first time demonstrated the safe use of intrape-
ritoneal epinephrine with intraperitoneal cisplatin in 18 patients with 
advanced peritoneal carcinomatosis [65]. Tumor responses were ob-
tained in some patients resistant to intravenous platinum compounds. 
Lidner et al., reported that concurrent intravenous administration of 
vasopressin can increase the pharmacokinetic advantage of intraperi-
toneal administered carboplatin and etoposide but not 5-FU [66]. 
Further studies on the use of vasoactive agents to improve cancer 
chemotherapy responses in PC are needed. 
DOSE OF INTRAPERITONEAL CANCER CHEMOTHER-
APY 
Many different chemotherapy agents, drug concentrations, drug 
doses, and drugs schedules have evolved at many institutions for 
perioperative cancer chemotherapy. Most authors use a drug dose 
based on calculated body surface area (mg/m
2) although Rubin et al., 
demonstrated that there is an imperfect correlation between actual 
peritoneal surface area and calculated body surface area [67]. The 
same study suggests sex differences in peritoneal surface areas which 
in turn might affect the absorption characteristics. The female has a 
larger peritoneal surface in proportion to body size than the male by 
approximately 10%. Estimates of the functional peritoneal surface 
area by applying stereologic methods to CT scans have been at-
tempted [68].  
Body surface area is an accurate predictor of drug metabolism 
and in this regard is useful for estimating systemic drug toxicity. As 
discussed by Sugarbaker et al., the accuracy of this prediction is in-
creased if the volume of chemotherapy solution is also determined by 
the body surface area [61]. With a constant total dose of chemother-
apy and chemotherapy solution the bone marrow exposure to cyto-
toxic drugs can be most accurately predicted. If these predictions are 
not available, the danger of overdosing some patients and underdos-
ing others will occur.  
A significant number of institutions using a closed method for in-
traoperative hyperthermic chemotherapy calculated the dose of can-
cer chemotherapy per liter by body surface area. The total amount of 
cancer chemotherapy is mixed in a large volume of carrier solution 
(usually six liters) that is placed in a reservoir. For example, Deraco 
et al. have used doxorubicin 15.25 mg/m
2/l and cisplatin 43 mg/m
2/l 
with the total volume of 6 liters [69, 70]. Gilly and coworkers have 
used mitomycin C 0.5 mg/kg and cisplatin 0.7 mg/kg in a total vol-
ume of 4 to 6 liters [71, 72]. In this method the amount of chemother-
apy solution in contact with the peritoneal surface is determined by 
multiple variables - the amount of distention (between 2 and 6 liters) 
of the abdominal cavity induced by the chemotherapy solution, the 
patient sex, the amount of ascites present preoperatively and the ex-
tent of the visceral resection.  
In summary, this system that allows a variable amount of chemo-
therapy solution may result in a less accurate prediction of plasma 
AUC. The total volume of intraperitoneal chemotherapy can vary 
widely betweens individuals. Increases in the volume of intraperito-
neal chemotherapy solution cause an increase in diffusion surface and 
an increase in the amount of drug from peritoneal space to plasma. 
DISTRIBUTION OF INTRAPERITONEAL CHEMOTHER-
APY 
A wide variety of open and closed intraperitoneal chemotherapy 
methods of administration have been described [73-77]. The closed 
abdomen techniques have the theoretical advantage of less heat loss 
during perfusion. Also, a reduction in environmental risk for the op-
erative team has been suggested. Open abdomen techniques will pro-
vide a better spatial distribution of the chemotherapy solution over the 
entire peritoneal surface. Also, a more uniform heat distribution is 
expected if the chemotherapy solution is manually stirred throughout 
the HIPEC. However, to date no study has been able to detect any 
occupational risk for the staff [78-80]. Elias et al. performed a pro-78    Current Drug Discovery Technologies, 2009, Vol. 6, No. 1  Speeten et al. 
spective phase I-II study comparing seven HIPEC perfusion tech-
niques [76]. Judgments regarding adequate spatial distribution were 
made by measurement of temperature at multiple sites. Using the 
closed system, temperature varied greatly throughout the abdomen 
and pelvis. The temperature became more uniform with an open ab-
domen and manual distribution. Spatial diffusion, studied by adding 
methylene blue to the perfusate, was incomplete in the closed abdo-
men techniques (Fig. 6). However, these differences in the delivery of 
HIPEC may be more theoretical than real. In studies to date only the 
extent of PC, the absence of extraperitoneal disease and the com-
pleteness of cytoreduction correlated with survival. A comparison of 
data from centers performing either closed or open abdomen tech-
niques suggest that the chemotherapy effects by open or closed meth-
ods may be similar. Long follow-up will be required to make an accu-
rate comparison. 
TIMING OF CANCER CHEMOTHERAPY IN RELATION 
TO TIMING OF THE SURGICAL INTERVENTION 
Neoadjuvant Bidirectional Chemotherapy 
Considering the clinical application of chemotherapy in PC pa-
tients, one can intervene at four possible points in the timeline. First, 
neoadjuvant bidirectional chemotherapy uses both the intraperitoneal 
and intravenous routes of chemotherapy administration. It has been 
explored as an option to reduce the extent of small PC nodules. Theo-
retically, it may facilitate definitive cytoreductive surgery after initial 
exploratory laparoscopy or laparotomy. This approach was acrony-
med as Neoadjuvant Intraperitoneal and Systemic chemotherapy 
(NIPS) [81]. Radiologic and clinical responses have been reported by 
several groups [81-83]. Although this strategy may reduce the tumor 
load to be addressed by cytoreductive surgery, it has several disad-
vantages. Adhesions from prior surgical interventions may interfere 
with adequate intraperitoneal drug distribution. Also, complete re-
sponses are very unusual so that further cytoreduction-chemotherapy 
is definitely necessary if the approach is curative. Neoadjuvant in-
traperitoneal chemotherapy has been reported to add to morbidity and 
mortality of further surgical treatment [84]. Extensive fibrosis as a 
response to chemotherapy may occur and make judgments concern-
ing the extent of peritoneal carcinomatosis difficult – even impossible 
to assess. 
Intraoperative Intraperitoneal Chemotherapy 
Intraoperative intraperitoneal chemotherapy has been the most 
widely explored modality with consistent clinical improved outcomes 
in many phase II trials and several phase III trials [12-24].  
Early Postoperative Intraperitoneal Chemotherapy 
Early postoperative intraperitoneal chemotherapy has some con-
ceptual advantages. It is administered after cytoreductive surgery at 
the time of minimal residual tumor burden. Also, intraperitoneal 
treatments initiated before wound healing occurs, can minimize non-
uniform drug distribution and eliminate residual cancer cell entrap-
ment in postoperative fibrin deposits. Proper selection of chemother-
apy agents based on pharmacologic principles suggests the use of 
cell-cycle specific drugs such as 5-fluorouracil and the taxanes. Most 
EPIC regimens are administered postoperatively day 1 to 5 or day 1 
to 4 through an inflow catheter and outflow drains placed at the time 
of cytoreductive surgery. EPIC can be applied with or without HIPEC 
[85].  
Long-term combined intraperitoneal and systemic chemotherapy. 
Markman et al. Alberts et al. and Armstrong plus coworkers demon-
strated in a phase III trials that intravenous plus intraperitoneal che-
motherapy improves survival in patients with optimally debulked 
stage III ovarian cancer as compared to intravenous chemotherapy 
alone [86-88]. This approach may be used as ‘chemotherapeutic 
bridging’ between incomplete initial surgery and definitive cy-
toreduction or second look surgery. This type of chemotherapy is an 
adjuvant and not a perioperative use of chemotherapy. Failure analy-
sis reported for cytoreductive surgery plus perioperative chemother-
apy determined recurrent cancer most frequently occurs within the 
abdominal and pelvic cavity [89, 90]. Although systemic metastases 
do occur, treatment failures rarely occur in liver, lungs or other sys-
temic sites. In order to optimize the treatment of patients with PC it is 
likely that the greatest benefit will occur from a combination of these 
four treatment strategies. 
DURATION 
A wide variety of durations for HIPEC have been reported rang-
ing from 30 to 120 minutes. The duration is not arbitrary and selec-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Spatial distribution of intraperitoneal methylene blue using the closed abdomen technique. Although the subcutaneous tissues were uniformly 
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tion should proceed according to the pharmacologic clearance of the 
chemotherapeutic drug.  
MACROMOLECULAR VEHICLES 
In recent years an increased interest in macromolecular vehicles 
and other modulations of chemotherapeutic agents as a means of 
exploiting the regional dose intensity has emerged. The results of this 
research are conflicting. Contrary to intuitive thinking macromole-
cules may penetrate more deeply in the subperitoneal space despite 
their lower diffusivities. The nature of the capillary permeability 
probably is the major factor responsible for this higher concentration 
in the subperitoneal space together with an increased role of convec-
tion [91]. One should be cautious to conclude that this increased 
penetration into the subperitoneal space results in increased drug 
absorption into tumor nodules. One should not assume that the 
neovascularity of tumor nodules has the same selectivity for macro-
molecules as normal capillaries [92]. A second obstacle to cancer 
chemotherapy penetration into tumor nodules concerns the interstitial 
pressures in tumor nodules. It is significantly higher than that of the 
surrounding tissue space [93]. Convection may reduce tumor penetra-
tion by macromolecules.  
INDIVIDUAL DRUG SENSITIVITY OF TUMORS WITH-
OUT AND WITH HYPERTHERMIA 
The selection of chemotherapeutic agents used in perioperative 
chemotherapy protocols has been based on research in chemothera-
peutic responses in systemic administration, on pharmacodynamic 
and pharmacokinetic properties of the drug in intraperitoneal admini-
stration, increased cytotoxicity with hyperthermia and synergy be-
tween chemotherapeutic agents. There is solid evidence supporting a 
tumor-specific heterogeneous activity of cytotoxic drugs in cell cul-
tures of different tumors [94, 95]. 
Mahteme et al. recently stated the same heterogeneous cytotoxic 
response of cytotoxic drugs in PC samples in a variety of tumors [96]. 
The clinical implication of these data justifies further research to-
wards an individualized selection of drugs in PC patients. However, it 
should be acknowledged that as yet there is no prospective data sup-
porting an improved clinical outcome from drug selection based on 
in-vitro drug sensitivity testing. 
BIDIRECTIONAL INTRAOPERATIVE CHEMOTHERAPY 
The three compartment model described above for peritoneal 
transport predicts transport by diffusion from the peritoneal com-
partment through a peritoneal and preperitoneal tissue layer to the 
plasma. Also, drugs move from the plasma compartment through the 
preperitoneal tissue layer to the peritoneal compartment. By combin-
ing intraoperative intravenous and intraoperative intraperitoneal can-
cer chemotherapy a bidirectional diffusion gradient is created through 
the intermediate tissue layer which contains the cancer nodules. This 
offers opportunities for optimizing cancer chemotherapy delivery to 
the target peritoneal tumor nodules. Elias and coworkers were the 
first to utilize this approach [60]. Further pharmacologic studies are 
needed to clarify the most efficient method of administration (con-
tinuous versus bolus versus repeated bolus), doses and choice of can-
cer chemotherapy drugs for this bidirectional approach. 
CONCLUSION AND FUTURE DIRECTIONS 
The administration of perioperative chemotherapy in patients 
with peritoneal carcinomatosis should be governed by pharmacologic 
principles. Patients who have minimal residual disease as a result of 
cytoreductive surgery are candidates for perioperative chemotherapy 
by the intraperitoneal and intravenous route. Hyperthermia of the 
intraperitoneal chemotherapy solution will increase the cytotoxicity 
of the drug within the peritoneal cavity. Heating of the peritoneal and 
preperitoneal tissues will maximize the systemic chemotherapy ef-
fects on carcinomatosis, a phenomenon known as heat targeting. Pe-
rioperative chemotherapy has become an important part of cancer 
treatment and should become a standard modality for prevention and 
treatment of a wide variety of cancers that involve the peritoneal 
surfaces. 
In November of 2006 a consensus meeting was held in Milan to 
address current standard of practice in the clinical application of cy-
toreductive surgery and hyperthermic intraperitoneal chemotherapy in 
the management of patients with cancer [97]. The applications, both 
for the prevention of carcinomatosis and the management of carci-
nomatosis, were explored and suggestions regarding the current stan-
dard of practice offered by the consensus group using the Delphi 
method. It was clear that for two diseases combined treatment is now 
considered the standard of care. For mucinous appendiceal neoplasms 
with peritoneal dissemination a curative treatment is available in 
three-quarters of the patients who have a minimally aggressive can-
cer. For those patients who had a complete cytoreduction, half are 
alive and well at 10 years. There are no 10 year survivors in the ab-
sence of these treatments. Similarly, in patients with peritoneal meso-
thelioma a prior standard of care using systemic chemotherapy of-
fered approximately a 1 year median survival [20]. Using cytoreduc-
tive surgery and perioperative intraperitoneal chemotherapy this me-
dian survival has been extended to 5 years. Also, patients with carci-
nomatosis from colon cancer who have a small volume of cancer 
disseminated to the peritoneal surfaces and who are able to undergo 
complete cytoreduction have a median survival of approximately 30 
months and a 5-year survival of approximately 40%. Again, this ap-
proach is considered a standard of care with small volume carcinoma-
tosis from colon cancer. The national health care systems of the 
Netherlands and France have approved this approach for colon carci-
nomatosis. In other countries in Europe, approval comes on a case-
by-case basis.  
In two other major diseases early results of treatment as studied in 
meta-analyses and systematic reviews suggest a role for this com-
bined treatment in ovarian cancer [21]. Treatment at the time of diag-
nosis was suggested by the consensus group as the most likely to 
favorably affect survival. Currently, this combined treatment is most 
frequently used as a salvage treatment after systemic chemotherapy 
has failed. Even in this setting the results strongly suggest prolonged 
survival. With gastric cancer the meta-analysis strongly suggests an 
adjuvant role for perioperative intraperitoneal chemotherapy in pre-
venting local-regional failure of this disease after gastrectomy. Al-
though this comprehensive approach to the treatment of primary gas-
tric cancer has only been widely employed in Korea, it has advocates 
worldwide. Also, the best palliation of gastric cancer with peritoneal 
seeding may come from neoadjuvant intraperitoneal and systemic 
chemotherapy in patients with peritoneal carcinomatosis from this 
disease. In addition, with this approach a small percentage of patients 
(approximately 20% of those treated) may come to a complete cy-
toreduction when gastrectomy and peritonectomy are utilized. 
Applications of this method of treatment are currently under 
investigation for pleural mesothelioma, endometrial cancer, and 
retroperitoneal and visceral sarcoma. 
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